McDermott + Bull has successfully placed Bill Ricketts, Ph.D., as the Head of Clinical Development and Carol Chen, Ph.D., as the Director of Clinical Development for Karius. They will lead and execute the company’s pivotal trials and will be responsible for driving their development to achieve adoption, reimbursement, and regulatory approvals for the Karius Test.

Bill was the Director of Clinical Affairs for Quantgene and the Vice President of Clinical Development for DxTerity Diagnostics before that. His extensive laboratory experience with multiple platforms and technologies will serve him as he leads the Karius Clinical Development team.

Carol most recently served as the Director of Regulatory and Clinical Affairs at Lucira Health where she played an instrumental role in growing the clinical team. She possesses a blend of regulatory and clinical experience and has a background in designing and leading numerous clinical studies to the commercial phase.

Karius is a life sciences company focused on generating genomic insights for infectious diseases with a non-invasive Karius Test that helps clinicians make rapid treatment decisions. The Karius laboratory is CLIA-certified and CAP-accredited to perform high-complexity clinical laboratory testing.

These executive searches were completed by McDermott + Bull Managing Directors Ken Dropiewski and Linda Sierra and Senior Executive Recruiter Allison Cox.